Roivant Sciences (ROIV) Scheduled to Post Quarterly Earnings on Tuesday

Roivant Sciences (NASDAQ:ROIV) is set to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The firm had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. During the same quarter in the previous year, the company posted ($0.38) earnings per share. The company’s revenue was up 155.1% compared to the same quarter last year. On average, analysts expect Roivant Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Roivant Sciences Stock Up 0.9 %

Shares of NASDAQ ROIV opened at $11.87 on Friday. The stock has a market capitalization of $8.78 billion, a P/E ratio of 2.13 and a beta of 1.24. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. Roivant Sciences has a one year low of $8.47 and a one year high of $13.06. The firm’s 50 day simple moving average is $11.79 and its two-hundred day simple moving average is $11.29.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ROIV. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Thursday, September 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Finally, Bank of America lifted their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.39.

Insider Buying and Selling

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now owns 617,470 shares in the company, valued at approximately $7,193,525.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the transaction, the chief operating officer now owns 617,470 shares of the company’s stock, valued at approximately $7,193,525.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Financial Lp Qvt sold 876,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the completion of the sale, the director now directly owns 22,179,358 shares in the company, valued at $262,160,011.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,577,309 shares of company stock valued at $42,151,184 over the last three months. Corporate insiders own 7.90% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.